Oxford Biomedica plc (OXB) Q2 2023 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Oxford Biomedica Plc.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:04.398 Everyone, obviously good morning to those on the other side of the ocean. 00:00:04.398 -- 00:00:07.002 Thank you for joining today's 00:00:07.002 -- 00:00:11.690 analyst briefing of our 23 interim results. 00:00:11.690 -- 00:00:16.939 It's a pleasure to speak to you today alongside with our chief financial 00:00:16.939 -- 00:00:22.087 officer, Stuart Painter, who many of you should know by now. 00:00:22.087 -- 00:00:27.234 And for the first time, our Chief Commercial Officer, Dr. 00:00:27.234 -- 00:00:31.941 Sébastien Ribault, who most of you will not have met probably before. 00:00:31.941 -- 00:00:37.268 Sébastien, thank you for joining. I will start by presenting our new strategy. 00:00:37.268 -- 00:00:41.675 Sébastien will provide the commercial update afterwards, and Stuart will follow with 00:00:41.675 -- 00:00:45.780 financial results for the first half of the year. 00:00:45.780 -- 00:00:51.483 After the presentation, we will open the room up for questions. 00:00:51.483 -- 00:00:56.513 We have a live webcast running, and for those joining us remotely, we 00:00:56.513 -- 00:01:01.903 will turn to you for any question after the presentation, and we'll also 00:01:01.903 -- 00:01:07.373 accept any written questions which will be responded by our investor 00:01:07.373 -- 00:01:11.176 relations team following the presentation. 00:01:12.408 -- 00:01:17.356 Our clear company-wide goal is to create a, 00:01:17.356 -- 00:01:20.420 why not the, world-leading 00:01:20.420 -- 00:01:27.008 quality and innovation-driven CDMO in the field of cell and gene therapy. 00:01:27.612 -- 00:01:32.660 I'm now six months into my role as CEO at Oxford Biomedica. 00:01:32.660 -- 00:01:39.273 I have spent the first months getting to really understand the...